Italia -
Italia -
AIFA (Agenzia Italiana del Farmaco)
mibispect
national centre for nuclear research - tecnezio-99mtc-sestamibi - tecnezio-99mtc-sestamibi
Tanzania -
Inggris -
Tanzania Medicinces & Medical Devices Authority
centre-ivermec injection 10
aether centre (beijing) biology co., limited, china - ivermectin - injection - 10
Uni Eropa -
Belanda -
EMA (European Medicines Agency)
mozobil
sanofi b.v. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - immunostimulants, - mozobil wordt aangegeven in combinatie met granulocyt-kolonie-stimulerende factor ter verbetering van de mobilisatie van hematopoïetische stamcellen naar het perifere bloed voor verzameling en latere autologe transplantatie bij patiënten met lymfoom en meerdere myeloma waarvan cellen slecht mobiliseren.
Finlandia -
Suomi -
Fimea (Suomen lääkevirasto)
diformin retard 500 mg depottabletti, kalvopäällysteinen
takeda oy takeda oy - metformini hydrochloridum - depottabletti, kalvopäällysteinen - 500 mg - metformiini
Finlandia -
Suomi -
Fimea (Suomen lääkevirasto)
diformin retard 750 mg depottabletti, kalvopäällysteinen
takeda oy takeda oy - metformini hydrochloridum - depottabletti, kalvopäällysteinen - 750 mg - metformiini
Finlandia -
Suomi -
Fimea (Suomen lääkevirasto)
diformin retard 1 g depottabletti, kalvopäällysteinen
takeda oy takeda oy - metformini hydrochloridum - depottabletti, kalvopäällysteinen - 1 g - metformiini
Uni Eropa -
Prancis -
EMA (European Medicines Agency)
mozobil
sanofi b.v. - plérixafor - multiple myeloma; hematopoietic stem cell transplantation; lymphoma - les immunostimulants, - mozobil est indiqué en association avec granulocyte-colony-stimulating factor pour renforcer la mobilisation des cellules souches hématopoïétiques dans le sang périphérique pour la collecte et l’autogreffe ultérieure chez des patients atteints de lymphome et multiple myélome dont les cellules mobiliser mal.
Australia -
Inggris -
Department of Health (Therapeutic Goods Administration)
zolacos cp combination goserelin 10.8mg (as acetate) implant syringe and bicalutamide 50mg tablet blister pack
astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment
Australia -
Inggris -
Department of Health (Therapeutic Goods Administration)
zolacos cp combination goserelin 3.6mg (as acetate) implant syringe and bicalutamide 50mg tablet blister pack
astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment.
Belgia -
Prancis -
AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)
concentré d'antithrombine iii baxalta 500 ui sol. inj./perf. (pdr. + solv.) i.v. flac.
baxalta innovations gmbh - antithrombine iii 500 ui/10 ml - poudre et solvant pour solution injectable/pour perfusion - 500 iu - antithrombine iii 50 ui/ml - antithrombin iii